Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

1.

Aggregation risk prediction for antibodies and its application to biotherapeutic development.

Obrezanova O, Arnell A, Cuesta RG, Berthelot ME, Gallagher TR, Zurdo J, Stallwood Y.

MAbs. 2015 Mar 4;7(2):352-63. doi: 10.1080/19420862.2015.1007828.

PMID:
25760769
2.

Small interfering RNA-mediated knockdown of notch ligands in primary CD4+ T cells and dendritic cells enhances cytokine production.

Stallwood Y, Briend E, Ray KM, Ward GA, Smith BJ, Nye E, Champion BR, McKenzie GJ.

J Immunol. 2006 Jul 15;177(2):885-95.

3.

Cellular Notch responsiveness is defined by phosphoinositide 3-kinase-dependent signals.

McKenzie G, Ward G, Stallwood Y, Briend E, Papadia S, Lennard A, Turner M, Champion B, Hardingham GE.

BMC Cell Biol. 2006 Feb 28;7:10.

4.

Notch: a unique therapeutic target for immunomodulation.

McKenzie GJ, Khan M, Briend E, Stallwood Y, Champion BR.

Expert Opin Ther Targets. 2005 Apr;9(2):395-410. Review.

PMID:
15934923
5.

RNA interference.

Stallwood Y.

Pharmacogenomics. 2005 Jan;6(1):13-6. Review. No abstract available.

PMID:
15723601
6.

Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.

Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW.

Gene Ther. 2001 Mar;8(5):341-8.

7.

Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients.

Stallwood Y, Fisher KD, Gallimore PH, Mautner V.

Gene Ther. 2000 Apr;7(8):637-43.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk